| Athens Insomnia Scale AIS | After four weeks, AIS sleep symptoms decreased by 0.95 points more than with placebo when pooling the 20 and 30 mg/day Safr’Inside groups.Adjusted AIS difference for pooled 20 and 30 mg versus placebo −0.95 points (95% CI −1.79…−0.11), p=0.027; mean changes −1.54 and −1.96 versus −0.71. | 2/4 LowPrecision of the estimate: Short follow-up and uncertain clinical relevance of the magnitude. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow study question. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Subjective outcomes, attrition, secondary comparisons. | 11 trialEffect of a saffron extract on sleep quality in adults with moderate insomnia: A decentralized, randomized, double-blind, placebo-controlled trial ↗ | 165 adults with moderate insomnia symptoms, 150 completed | - Effect of a saffron extract on sleep quality in adults with moderate insomnia: A decentralized, randomized, double-blind, placebo-controlled trial ↗
|
|---|
| Single-item Sleep Quality Scale SQS | After four weeks, self-rated SQS sleep quality was 1.02 points higher with 20 mg/day Safr’Inside than with placebo.At week 4, adjusted SQS contrast +1.02 points (95% CI +0.43…+1.62), p<0.001 for 20 mg versus placebo. | 2/4 LowPrecision of the estimate: Short follow-up and uncertain clinical relevance of the magnitude. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow study question. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Subjective outcomes, attrition, secondary comparisons. | 11 trialEffect of a saffron extract on sleep quality in adults with moderate insomnia: A decentralized, randomized, double-blind, placebo-controlled trial ↗ | 165 adults with moderate insomnia symptoms, 150 completed | - Effect of a saffron extract on sleep quality in adults with moderate insomnia: A decentralized, randomized, double-blind, placebo-controlled trial ↗
|
|---|
| Single-item Sleep Quality Scale SQS | After four weeks, self-rated SQS sleep quality was 0.82 points higher with 30 mg/day Safr’Inside than with placebo.At week 4, adjusted SQS contrast +0.82 points (95% CI +0.22…+1.41), p=0.004 for 30 mg versus placebo. | 2/4 LowPrecision of the estimate: Short follow-up and uncertain clinical relevance of the magnitude. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow study question. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Subjective outcomes, attrition, secondary comparisons. | 11 trialEffect of a saffron extract on sleep quality in adults with moderate insomnia: A decentralized, randomized, double-blind, placebo-controlled trial ↗ | 165 adults with moderate insomnia symptoms, 150 completed | - Effect of a saffron extract on sleep quality in adults with moderate insomnia: A decentralized, randomized, double-blind, placebo-controlled trial ↗
|
|---|
| Mood, anxiety and fatigue with mild symptoms | Activ’Inside showed no advantage over placebo in the overall score for low mood, anxiety and fatigue or its individual components.No significant between-group difference was shown for the composite or its individual components. | 2/4 Lowrisk_of_bias: Several outcomes and self-ratings. inconsistency: There are no grounds for a separate downgrade. indirectness: The measurement directly answers the specific narrow PICO. imprecision: 51 participants; exact CI of the comparative effect not confirmed. publication_bias: There are no specific data for a separate downgrade. | 11 trialEffect of saffron extract supplementation on mood in healthy adults with subclinical symptoms of depression: a randomized, double-blind placebo-controlled study. ↗ | 51 adults with subclinical depressive symptoms | - Effect of saffron extract supplementation on mood in healthy adults with subclinical symptoms of depression: a randomized, double-blind placebo-controlled study. ↗
|
|---|
| Depressive symptoms: clinician rating with added affron | Adding affron to an antidepressant reduced clinician-rated depressive symptoms more.Reduction 41.28% versus 20.59%, d=0.58, p=0.001. | 1/4 Very lowrisk_of_bias: Attrition and differing results on two primary scales. inconsistency: There are no grounds for a separate downgrade. indirectness: Only adjunct use of the formulation studied in the clinical group. imprecision: One experiment, incomplete precision of the estimate. publication_bias: There are no specific data for a separate downgrade. | 11 trialEfficacy of a standardised saffron extract (affron®) as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults: A randomised, double-blind, placebo-controlled study ↗ | 160 adults with persistent depressive symptoms on an antidepressant; 139 with usable data | - Efficacy of a standardised saffron extract (affron®) as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults: A randomised, double-blind, placebo-controlled study ↗
|
|---|
| Depressive symptoms: self-rating with added affron | Adding affron to an antidepressant showed no advantage in participants' own symptom ratings.Reduction 26.81% versus 26.00%, p=0.831; interaction p=0.907. | 1/4 Very lowrisk_of_bias: Attrition and differing results on two primary scales. inconsistency: There are no grounds for a separate downgrade. indirectness: Only adjunct use of the formulation studied in the clinical group. imprecision: One experiment, incomplete precision of the estimate. publication_bias: There are no specific data for a separate downgrade. | 11 trialEfficacy of a standardised saffron extract (affron®) as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults: A randomised, double-blind, placebo-controlled study ↗ | 160 adults with persistent depressive symptoms on an antidepressant; 139 with usable data | - Efficacy of a standardised saffron extract (affron®) as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults: A randomised, double-blind, placebo-controlled study ↗
|
|---|
| Overall sexual function score | The overall sexual function score gave a borderline result.Time×treatment interaction p=0.050. | 1/4 Very lowrisk_of_bias: Attrition and several subscale comparisons. inconsistency: There are no grounds for a separate downgrade. indirectness: Selected clinical group, limited transfer to overall well-being. imprecision: Effect size with CI not confirmed. publication_bias: There are no specific data for a separate downgrade. | 11 trialCrocus sativus (saffron) in the treatment of female sexual dysfunction: a three-center, double-blind, randomized, and placebo-controlled clinical trial. ↗ | 74 women aged 18–55 with sexual dysfunction, 68 completed | - Crocus sativus (saffron) in the treatment of female sexual dysfunction: a three-center, double-blind, randomized, and placebo-controlled clinical trial. ↗
|
|---|
| Sexual desire | In the study of women with sexual difficulties, desire ratings improved in favour of saffron.Interaction p=0.007. | 1/4 Very lowrisk_of_bias: Attrition and several subscale comparisons. inconsistency: There are no grounds for a separate downgrade. indirectness: Selected clinical group, limited transfer to overall well-being. imprecision: Effect size with CI not confirmed. publication_bias: There are no specific data for a separate downgrade. | 11 trialCrocus sativus (saffron) in the treatment of female sexual dysfunction: a three-center, double-blind, randomized, and placebo-controlled clinical trial. ↗ | 74 women aged 18–55 with sexual dysfunction, 68 completed | - Crocus sativus (saffron) in the treatment of female sexual dysfunction: a three-center, double-blind, randomized, and placebo-controlled clinical trial. ↗
|
|---|
| Lubrication during sexual activity | In the study of women with sexual difficulties, lubrication ratings improved in favour of saffron.Interaction p=0.018. | 1/4 Very lowrisk_of_bias: Attrition and several subscale comparisons. inconsistency: There are no grounds for a separate downgrade. indirectness: Selected clinical group, limited transfer to overall well-being. imprecision: Effect size with CI not confirmed. publication_bias: There are no specific data for a separate downgrade. | 11 trialCrocus sativus (saffron) in the treatment of female sexual dysfunction: a three-center, double-blind, randomized, and placebo-controlled clinical trial. ↗ | 74 women aged 18–55 with sexual dysfunction, 68 completed | - Crocus sativus (saffron) in the treatment of female sexual dysfunction: a three-center, double-blind, randomized, and placebo-controlled clinical trial. ↗
|
|---|
| Satisfaction with sexual life | In the study of women with sexual difficulties, satisfaction ratings improved in favour of saffron.Interaction p=0.007. | 1/4 Very lowrisk_of_bias: Attrition and several subscale comparisons. inconsistency: There are no grounds for a separate downgrade. indirectness: Selected clinical group, limited transfer to overall well-being. imprecision: Effect size with CI not confirmed. publication_bias: There are no specific data for a separate downgrade. | 11 trialCrocus sativus (saffron) in the treatment of female sexual dysfunction: a three-center, double-blind, randomized, and placebo-controlled clinical trial. ↗ | 74 women aged 18–55 with sexual dysfunction, 68 completed | - Crocus sativus (saffron) in the treatment of female sexual dysfunction: a three-center, double-blind, randomized, and placebo-controlled clinical trial. ↗
|
|---|
| Overall PMS symptoms | In the review of different saffron capsules, overall PMS symptom severity decreased.SMD −0.64 (95% CI −0.84…−0.44), trim-and-fill −0.59 (−0.78…−0.41). | 1/4 Very lowrisk_of_bias: Mixed designs and quality limitations. inconsistency: Different scales and unstable estimates between analyses. indirectness: Different forms and control conditions. imprecision: Enough data for a limited conclusion. publication_bias: There are no specific data for a separate downgrade. | 11 named reviewEffect of saffron on premenstrual syndrome and dysmenorrhea: a systematic review and meta-analysis. ↗ | Women with PMS in the review's studies; ages and designs varied. | - Effect of saffron on premenstrual syndrome and dysmenorrhea: a systematic review and meta-analysis. ↗
|
|---|
| Menstrual pain | The initial signal of reduced menstrual pain did not persist after correction for possible publication bias.SMD −0.51 (95% CI −1.01…−0.01), trim-and-fill −0.01 (−0.66…+0.46). | 1/4 Very lowrisk_of_bias: Mixed designs and quality limitations. inconsistency: Different scales and unstable estimates between analyses. indirectness: Different forms and control conditions. imprecision: Enough data for a limited conclusion. publication_bias: There are no specific data for a separate downgrade. | 11 named reviewEffect of saffron on premenstrual syndrome and dysmenorrhea: a systematic review and meta-analysis. ↗ | Women with dysmenorrhoea in the review's studies; in Lopresti this is a secondary outcome. | - Effect of saffron on premenstrual syndrome and dysmenorrhea: a systematic review and meta-analysis. ↗
|
|---|